2021
Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion
Darden D, Duong T, Du C, Munir MB, Han FT, Reeves R, Saw J, Zeitler EP, Al-Khatib SM, Russo AM, Minges KE, Curtis JP, Freeman JV, Hsu JC. Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion. JAMA Cardiology 2021, 6: 1275-1284. PMID: 34379072, PMCID: PMC8358791, DOI: 10.1001/jamacardio.2021.3021.Peer-Reviewed Original ResearchConceptsHospital adverse eventsMajor adverse eventsAdverse eventsAtrial appendage occlusionMajor bleedingPericardial effusionAppendage occlusionAtrial fibrillationSex differencesCongestive heart failureCoronary artery diseaseAdjusted logistic regression analysisParoxysmal atrial fibrillationLogistic regression analysisMultivariable adjusted logistic regression analysesPrior strokeUncontrolled hypertensionHospital outcomesHospital stayMultivariable adjustmentProlonged hospitalBaseline characteristicsCohort studySelect patientsArtery disease
2020
Patterns of oral anticoagulation use with cardioversion in clinical practice
Geurink K, Holmes D, Ezekowitz MD, Pieper K, Fonarow G, Kowey PR, Reiffel JA, Singer DE, Freeman J, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli G, Piccini JP, Peterson ED, Pokorney SD. Patterns of oral anticoagulation use with cardioversion in clinical practice. Heart 2020, 107: 642-649. PMID: 32591363, DOI: 10.1136/heartjnl-2019-316315.Peer-Reviewed Original ResearchConceptsStroke/transient ischemic attackVitamin K antagonistsNovel oral anticoagulantsTransient ischemic attackTransoesophageal echocardiogramAtrial fibrillationClinical practiceAtrial Fibrillation IIOral anticoagulation useTime of cardioversionBetter Informed TreatmentMonths of enrollmentIncidence of deathLow-risk procedureSimilar ratesAnticoagulation useIschemic attackMajor bleedingK antagonistsOral anticoagulantsClinical outcomesOutcomes RegistryCardiovascular hospitalisationAF diagnosisInclusion criteriaSwitching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry
Sciria CT, Maddox TM, Marzec L, Rodwin B, Virani SS, Annapureddy A, Freeman JV, O'Hare A, Liu Y, Song Y, Doros G, Zheng Y, Lee JJ, Daggubati R, Vadlamani L, Cannon C, Desai NR. Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry. Clinical Cardiology 2020, 43: 743-751. PMID: 32378265, PMCID: PMC7368350, DOI: 10.1002/clc.23376.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsAF patientsAtrial fibrillationOral anticoagulantsAvailability of DOACsChronic warfarin therapyMultivariable hierarchical regressionNCDR PINNACLE RegistryPattern of anticoagulationProspective cohort studyPractice-level factorsPractice-level variationPINNACLE RegistryPrescribed warfarinSwitched patientsClinical characteristicsCohort studyStroke riskWarfarin therapyCurrent guidelinesPatientsWarfarinAnticoagulationPrivate insuranceSignificant predictors
2018
Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.
Essien UR, Holmes DN, Jackson LR, Fonarow GC, Mahaffey KW, Reiffel JA, Steinberg BA, Allen LA, Chan PS, Freeman JV, Blanco RG, Pieper KS, Piccini JP, Peterson ED, Singer DE. Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiology 2018, 3: 1174-1182. PMID: 30484833, PMCID: PMC6583087, DOI: 10.1001/jamacardio.2018.3945.Peer-Reviewed Original ResearchConceptsDirect-acting oral anticoagulantsAtrial Fibrillation IIOral anticoagulant useOral anticoagulantsBetter Informed TreatmentAtrial fibrillationAnticoagulant useRace/ethnicityWhite individualsOutcomes RegistryHispanic individualsBlack individualsInformed TreatmentOne-year persistenceOral anticoagulant discontinuationQuality of anticoagulationEthnic differencesSelf-reported race/ethnicitySocioeconomic factorsQuality of careHispanic groupsAnticoagulant discontinuationDOAC useInappropriate dosingCohort studyPharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
Washam JB, Holmes DN, Thomas LE, Pokorney SD, Hylek EM, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Ansell JE, Go AS, Reiffel JA, Freeman JV, Singer DE, Naccarelli G, Blanco R, Peterson ED, Piccini JP. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF. Journal Of The American Heart Association 2018, 7: e008928. PMID: 30371218, PMCID: PMC6222961, DOI: 10.1161/jaha.118.008928.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationDabigatranDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesRegistriesRenal Insufficiency, ChronicRisk FactorsStrokeTime FactorsTreatment OutcomeWarfarinConceptsBackground Chronic kidney diseaseAntiarrhythmic drug useTransient ischemic attackChronic kidney diseaseAtrial fibrillationAdvanced CKDCKD statusIschemic attackSystemic embolismCause mortalityCreatinine clearanceRhythm controlKidney diseaseDrug useAtrial fibrillation scoreBaseline renal functionOral anticoagulant useRhythm control strategyCox proportional hazardsCKD patientsMajor bleedingOAC useCardiovascular deathCKD stageHigher CHA
2017
Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry
Kipp R, Hsu JC, Freeman J, Curtis J, Bao H, Hoffmayer KS. Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry. Heart Rhythm 2017, 15: 847-854. PMID: 28987459, DOI: 10.1016/j.hrthm.2017.09.043.Peer-Reviewed Original ResearchConceptsCause mortalityMedicare beneficiariesICD implantationProcedural complicationsHospital characteristicsMultivariable Cox proportional hazards regression analysisNational Cardiovascular Data Registry ICD RegistryCox proportional hazards regression analysisFirst-time ICD recipientsImplantable cardioverter defibrillator implantationNational Cardiovascular Data RegistryProportional hazards regression analysisKaplan-Meier survival analysisLong-term morbidityPredictors of mortalityCardioverter-defibrillator implantationOccurrence of complicationsRetrospective registry studyAcute procedural complicationsHazards regression analysisLong-term outcomesRisk of mortalityMortality 3 yearsIndex hospitalizationRegistry study
2015
Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes
Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Chang P, Peterson ED, Piccini JP. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes. Circulation Cardiovascular Quality And Outcomes 2015, 8: 393-402. PMID: 26058720, DOI: 10.1161/circoutcomes.114.001303.Peer-Reviewed Original ResearchConceptsQuality of lifeAtrial fibrillationHigh riskAF patientsAF symptomsPatient outcomesSymptom severityAtrial Fibrillation EffectBorderline higher riskMajor adverse eventsBetter Informed TreatmentAtrial fibrillation symptomsCommunity-based studyAFEQT scoreEHRA classMajor bleedingMost patientsSymptom burdenAdverse eventsOutcomes RegistryCox regressionLife QuestionnaireFibrillation EffectInformed TreatmentPatientsImpact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, Hylek EM, Mahaffey KW, Freeman JV, Chang P, Holmes DN, Peterson ED, Piccini JP, Gersh BJ, Investigators O. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal 2015, 169: 647-654.e2. PMID: 25965712, DOI: 10.1016/j.ahj.2014.12.024.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaBetter Informed TreatmentAtrial fibrillationOutcomes RegistrySleep apneaHigh riskStroke/transient ischemic attackContinuous positive airway pressure (CPAP) treatmentContinuous positive airway pressure therapyPrevalence of OSAInformed TreatmentImpact of OSAPositive airway pressure therapyPositive airway pressure treatmentAF progression rateHierarchical logistic regression modelingMajor cardiovascular outcomesRhythm control therapyAirway pressure therapyTransient ischemic attackLong-term outcomesRisk of deathLogistic regression modelingMore persistent formsCV death
2013
Effectiveness of β-Blockers in Heart Failure With Left Ventricular Systolic Dysfunction and Chronic Kidney Disease
Chang TI, Yang J, Freeman JV, Hlatky MA, Go AS. Effectiveness of β-Blockers in Heart Failure With Left Ventricular Systolic Dysfunction and Chronic Kidney Disease. Journal Of Cardiac Failure 2013, 19: 176-182. PMID: 23482078, PMCID: PMC4126798, DOI: 10.1016/j.cardfail.2013.01.006.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseVentricular systolic dysfunctionΒ-blocker therapyHeart failure hospitalizationIncident heart failureHeart failureKidney diseaseSystolic dysfunctionFailure hospitalizationΒ-blockersLower riskKaiser Permanente Northern California systemLeft ventricular systolic dysfunctionLower crude riskCombined end pointΒ-blocker useGlomerular filtration rateAssociation of treatmentMultivariable adjustmentCrude riskMedication effectivenessCox regressionPotential confoundersFiltration rateMethodologic limitations
2008
Prediction of Cardiovascular Death using a Novel Heart Rate Recovery Parameter
HADLEY DM, DEWEY FE, FREEMAN JV, MYERS JN, FROELICHER VF. Prediction of Cardiovascular Death using a Novel Heart Rate Recovery Parameter. Medicine & Science In Sports & Exercise 2008, 40: 1072-1079. PMID: 18460999, DOI: 10.1249/mss.0b013e318167665a.Peer-Reviewed Original ResearchConceptsDuke treadmill scoreHeart rate recoveryHR increaseCV mortalityVagal toneCardiovascular causesCardiovascular deathPeak exerciseLowest tertileTreadmill scoreCox analysisClinical parametersMaximal exerciseSympathetic influencesExercise indexRate recoveryVagal influencePrognostic measurementMortalityPatientsRecovery variablesNormal scoresScoresExerciseRecovery parameters
2007
Novel predictor of prognosis from exercise stress testing: Heart rate variability response to the exercise treadmill test
Dewey FE, Freeman JV, Engel G, Oviedo R, Abrol N, Ahmed N, Myers J, Froelicher VF. Novel predictor of prognosis from exercise stress testing: Heart rate variability response to the exercise treadmill test. American Heart Journal 2007, 153: 281-288. PMID: 17239690, DOI: 10.1016/j.ahj.2006.11.001.Peer-Reviewed Original ResearchMeSH KeywordsExercise TestFemaleFollow-Up StudiesHeart RateHumansMaleMiddle AgedPredictive Value of TestsPrognosisRetrospective StudiesConceptsHeart rate variabilitySquare successive differenceCardiovascular mortalityPrognostic powerHF powerExercise treadmill testingRoot mean square successive differenceFrequency-domain HRV analysisExercise stress testingExercise treadmill testMortality end pointsSuccessive differencesStandard exercise testingHeart rate variability responsesMinutes of recoveryStrongest predictorLow-frequency powerMean square successive differenceHigh-frequency powerR interval dataCardiovascular deathCause mortalityPeak exerciseClinical factorsExercise testing